医学
贝伐单抗
结直肠癌
生物仿制药
内科学
肿瘤科
卡培他滨
作者
Enrique Roca,Yuriy Vinnyk,Igor Bondarenko,Yaroslav Shparyk,Giovanni M. Bariani,Kathia Cristina Abdalla,Fabio Franke,Felipe Melo Cruz,Alvaro Romera,Sulabhchandra Bhamare,Suresh Sudalaiandi,Vikas Ostwal,Pradeep Shah,Sajeed Abdul Rahuman,Antonio Cubillo,Camino Huerga,Alexandra Paravisini,Francisco Javier Fernandez,Susana Millan
标识
DOI:10.1200/jco.2017.35.15_suppl.e14065
摘要
Background: BEVZ92 has being developed as a proposed biosimilar approved reference medicine product (RMP). BEVZ92 has an identical amino acid sequence and highly similar physicochemical and in vitro functional properties to RMP. The aim of this study was to demonstrate pharmacokinetics (PK) similarity of BEVZ92 to RMP, in combination in combination with FOLFOX or FOLFIRI, as first-line treatment in patients with mCRC (NCT02069704). Methods: PK analysis for multiple dose studies was conducted, ...
科研通智能强力驱动
Strongly Powered by AbleSci AI